EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Factors Associated with Increased Healthcare Utilization Within 30 and 90 Days Post-Discharge of CAR-T Cell Therapy in Patients with R/R LBCL

Philip Yeung, Aaron Trando, Ah-Reum Jeong iD, Dimitrios Tzachanis iD

Hematology Reports · 27.07.2026 · 18 (4) · 52

DOI: 10.3390/hematolrep18040052 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hematology Reports, online erschienen am 27.07.2026. Verfasst von Philip Yeung und 3 weiteren Autor:innen. Beteiligte Einrichtung: Master of Advanced Studies (MAS) Program in Clinical Research, University of California San Diego, La Jolla, CA 92093, USA. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: CAR T-cell therapy is a highly efficacious therapy option for relapsed/refractory (R/R) large B-cell lymphoma (LBCL), but its widespread use is currently limited by safety concerns and high healthcare costs.

Methods

We evaluated 66 patients with R/R LBCL treated with tisagenlecleucel or axicabtagene ciloleucel between 2016 and 2022 at a single institution to identify factors associated with increased healthcare utilization.

Results

The median age of our cohort was 59.5 years, with 22.7% over the age of 70. The median length of stay (LOS) during the initial hospitalization was 12 days (range, 7–62 days). Longer initial hospital LOS was linked to higher age-adjusted HCT-CI score (IRR 1.08; 95% CI, 1.01 to 1.15; p = 0.0203), thrombocytopenia grade 3–4 (IRR 1.32; 95% CI, 1.07 to 1.63; p = 0.0091), and first ICU admission (IRR 1.81; 95% CI, 1.37 to 2.38; p < 0.00001). Thirty- and 90-day readmission rates post-discharge after receiving CAR T-cell therapy were 21.2% and 28.8%, respectively. Multiple readmissions within 90 days after initial hospital discharge were observed in 15% of patients. Longer 30-day readmission LOS was linked to initial hospital LOS (IRR 1.23; 95% CI, 1.11 to 1.35; p < 0.0001) but outpatient follow-up was associated with shorter 30-day readmission LOS (IRR 0.43; 95% CI, 0.26–0.69; p = 0.0005). Factors associated with longer 90-day readmission LOS included a greater number of ER visits within 60 days of CAR T-cell therapy (IRR 3.10; 95% CI, 2.15–4.46), prior 30-day readmission LOS (IRR 1.35; 95% CI, 1.14–1.60), and SUVmax at Day 30 (IRR 1.06; 95% CI, 1.03–1.09) (all p-values < 0.0001).

Conclusions

Our findings identify key clinical and utilization variables associated with initial and repeat hospitalizations post-CAR T-cell therapy, emphasizing the need for targeted interventions to reduce readmissions and optimize post-discharge care.

Schlagwörter

Stichwörter der Autor:innen

allogeneic hematopoietic stem cell transplantaxicabtagene ciloleucelchimeric antigen receptor T-cell therapyhealthcare utilizationhospital length of stayhospital readmissionlarge B-cell lymphomatisagenlecleucel

Autor:innen und Institutionen

  • Master of Advanced Studies (MAS) Program in Clinical Research, University of California San Diego, La Jolla, CA 92093, USA.
  • KUMC Master of Science Health Data Science Program, University of Kansas Medical Center, Kansas City, KS 66160, USA.
  • Department of Internal Medicine, University of California San Diego, La Jolla, CA 92093, USA.
  • Department of Medicine, Division of Blood and Marrow Transplantation, University of California San Diego, La Jolla, CA 92093, USA.
  • Division of Hematology/Oncology, Scripps Cancer Center, La Jolla, CA 92037, USA.

ORCID-Profile: Ah-Reum Jeong, Dimitrios Tzachanis

Zitieren

APA

Yeung, P., Trando, A., Jeong, A. R., & Tzachanis, D. (2026). Factors Associated with Increased Healthcare Utilization Within 30 and 90 Days Post-Discharge of CAR-T Cell Therapy in Patients with R/R LBCL. Hematology Reports, 18(4), 52. https://doi.org/10.3390/hematolrep18040052

Vancouver

Yeung P, Trando A, Jeong AR, Tzachanis D. Factors Associated with Increased Healthcare Utilization Within 30 and 90 Days Post-Discharge of CAR-T Cell Therapy in Patients with R/R LBCL. Hematology Reports. 2026;18(4):52. doi:10.3390/hematolrep18040052

BibTeX
@article{Yeung2026,
  author = {Yeung, Philip and Trando, Aaron and Jeong, Ah-Reum and Tzachanis, Dimitrios},
  title = {Factors Associated with Increased Healthcare Utilization Within 30 and 90 Days Post-Discharge of CAR-T Cell Therapy in Patients with R/R LBCL},
  journal = {Hematology Reports},
  year = {2026},
  volume = {18},
  number = {4},
  pages = {52},
  doi = {10.3390/hematolrep18040052}
}
Kostenlos starten →